New investigations into retatrutide, a dual agonist for GLP-1 and GIP receptors, are revealing significant results in managing obesity and diabetes 2 condition. Preclinical data suggest a unique mechanism contributing https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/